Havrix Adult (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Adult is indicated for the prevention of hepatitis A virus infection in adults.

• Primary prophylaxis for travelers to regions where hepatitis A is endemic.
• Post‑exposure prophylaxis for individuals who have had recent contact with a confirmed case.
• Immunization of persons with chronic liver disease to reduce risk of severe outcomes.
• Use in outbreak control settings to quickly protect at‑risk populations.
• Vaccination of healthcare workers who may be exposed to hepatitis A through occupational contact.
• Administration to individuals planning to receive blood products, ensuring immunity before transfusion.

The safety profile of Havrix Adult reflects typical vaccine reactions, most of which are mild, transient, and resolve without medical intervention. These reactions are generally self‑limiting and do not require specific treatment.

Common

• Mild pain, redness, or swelling at the injection site lasting one to two days.
• Low‑grade fever (up to 38 °C) that may often accompany mild fatigue.
• Transient headache or muscle aches that usually resolve within 24–48 hours.

Serious

• Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, hives, and swelling.
• Guillain‑Barré syndrome, a rare neurological disorder presenting with muscle weakness.
• High fever persisting longer than 48 hours, possibly accompanied by chills.

Before administering Havrix Adult, healthcare providers should assess patient history and consider specific safety considerations in clinical practice for the patient to minimize risk and ensure optimal vaccine response.

• Severe allergy to any vaccine component, particularly algeldrate, contraindicates use.
• History of anaphylaxis after a previous hepatitis A vaccine dose requires medical evaluation.
• Moderate or severe acute illness at the time of vaccination should be postponed.
• Immunocompromised patients may develop a reduced antibody response and should be monitored.
• Pregnant or breastfeeding women should discuss potential risks and benefits with their clinician.
• Individuals with chronic liver disease should be vaccinated, but efficacy should be assessed periodically.

Havrix Adult may interact with other agents; clinicians should review concomitant medications, vaccines, and immune‑modulating therapies to avoid reduced efficacy or increased adverse events in clinical settings for patient safety.

Avoid

• Simultaneous administration of other live viral vaccines at the same injection site.
• Co‑administration with hepatitis A immune globulin intended for prophylaxis.

Use with caution

• Patients receiving immunosuppressive therapy may have a diminished immune response to the vaccine.
• Prophylactic antipyretics can mask fever, a common post‑vaccination sign.
• Blood products given shortly before or after vaccination may affect antibody development.
• Concurrent use of high‑dose steroids may reduce vaccine immunogenicity.